share_log

Insmed | 10-Q: Q2 2024 Earnings Report

Insmed | 10-Q: Q2 2024 Earnings Report

Insmed | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 19:04

Moomoo AI 已提取核心信息

Insmed reported strong Q2 2024 financial results with product revenues increasing 17% to $90.3 million, driven by ARIKAYCE sales growth across all regions. US sales rose 10.6% to $63.8 million, while Japan and Europe saw growth of 35.4% and 36.9% respectively. The company ended the quarter with $1.25 billion in cash and cash equivalents.The company announced positive topline results from its Phase 3 ASPEN trial of brensocatib, meeting its primary endpoint with both dosage strengths demonstrating statistically significant reductions in pulmonary exacerbations versus placebo. Based on these results, Insmed plans to file an NDA with the FDA in Q4 2024, followed by European and Japanese regulatory submissions.R&D expenses decreased to $146.7 million from $197.0 million year-over-year, while SG&A expenses increased 26.2% to $106.6 million due to higher compensation costs and commercial readiness activities. The company strengthened its financial position through a successful equity offering in May 2024, raising net proceeds of $713.2 million.
Insmed reported strong Q2 2024 financial results with product revenues increasing 17% to $90.3 million, driven by ARIKAYCE sales growth across all regions. US sales rose 10.6% to $63.8 million, while Japan and Europe saw growth of 35.4% and 36.9% respectively. The company ended the quarter with $1.25 billion in cash and cash equivalents.The company announced positive topline results from its Phase 3 ASPEN trial of brensocatib, meeting its primary endpoint with both dosage strengths demonstrating statistically significant reductions in pulmonary exacerbations versus placebo. Based on these results, Insmed plans to file an NDA with the FDA in Q4 2024, followed by European and Japanese regulatory submissions.R&D expenses decreased to $146.7 million from $197.0 million year-over-year, while SG&A expenses increased 26.2% to $106.6 million due to higher compensation costs and commercial readiness activities. The company strengthened its financial position through a successful equity offering in May 2024, raising net proceeds of $713.2 million.
Insmed报告了2024年第二季度强劲的财务业绩，产品收入增长17%，达到9030万美元，这得益于ARIKAYCE在所有地区的销售增长。美国销售额增长10.6%，达到6380万美元，而日本和欧洲分别增长35.4%和36.9%。公司季度末现金及现金等价物为12.5亿。公司宣布了其第三阶段ASPEN试验brensocatib的积极总体结果，达到了其主要终点，两个剂量强度在肺部加重方面相比安慰剂均显示出统计学显著的减少。基于这些结果，Insmed计划在2024年第四季度向FDA提交新药申请，随后进行欧洲和日本的监管提交。研发费用同比减少至14670万美元，从19700万美元下降，而销售、一般及行政费用因更高的薪酬成本和商业准备活动增加26.2%，达到10660万美元。公司通过2024年5月成功的股权融资增强了其财务状况，净收益为71320万美元。
Insmed报告了2024年第二季度强劲的财务业绩，产品收入增长17%，达到9030万美元，这得益于ARIKAYCE在所有地区的销售增长。美国销售额增长10.6%，达到6380万美元，而日本和欧洲分别增长35.4%和36.9%。公司季度末现金及现金等价物为12.5亿。公司宣布了其第三阶段ASPEN试验brensocatib的积极总体结果，达到了其主要终点，两个剂量强度在肺部加重方面相比安慰剂均显示出统计学显著的减少。基于这些结果，Insmed计划在2024年第四季度向FDA提交新药申请，随后进行欧洲和日本的监管提交。研发费用同比减少至14670万美元，从19700万美元下降，而销售、一般及行政费用因更高的薪酬成本和商业准备活动增加26.2%，达到10660万美元。公司通过2024年5月成功的股权融资增强了其财务状况，净收益为71320万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点